Vivid

Vividion Therapeutics is a biotechnology company focused on discovering and developing precision therapeutics for previously undrugged targets. The company utilizes a proprietary chemoproteomics platform that combines covalent chemistry with high-throughput screening to identify novel binding pockets on proteins that were historically considered inaccessible to small molecules. Acquired by Bayer in 2021 for $1.5 billion, Vividion operates as an independent subsidiary, advancing a pipeline primarily focused on oncology and immunology. Its lead programs include inhibitors for WRN helicase and activators for the KEAP1-NRF2 pathway, aimed at treating various cancers and inflammatory conditions.